276 related articles for article (PubMed ID: 29641297)
1. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.
Jonasch E; Slack RS; Geynisman DM; Hasanov E; Milowsky MI; Rathmell WK; Stovall S; Juarez D; Gilchrist TR; Pruitt L; Ornstein MC; Plimack ER; Tannir NM; Rini BI
J Clin Oncol; 2018 Jun; 36(16):1588-1593. PubMed ID: 29641297
[TBL] [Abstract][Full Text] [Related]
2. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.
Bjarnason GA; Knox JJ; Kollmannsberger CK; Soulieres D; Ernst DS; Zalewski P; Canil CM; Winquist E; Hotte SJ; North SA; Heng DYC; Macfarlane RJ; Venner PM; Kapoor A; Hansen AR; Eigl BJ; Czaykowski P; Boyd B; Wang L; Basappa NS
Eur J Cancer; 2019 Feb; 108():69-77. PubMed ID: 30648632
[TBL] [Abstract][Full Text] [Related]
4. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
Mouillet G; Paillard MJ; Maurina T; Vernerey D; Nguyen Tan Hon T; Almotlak H; Stein U; Calcagno F; Berthod D; Robert E; Meurisse A; Thiery-Vuillemin A
Trials; 2018 Apr; 19(1):221. PubMed ID: 29650037
[TBL] [Abstract][Full Text] [Related]
5. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.
Lee JL; Kim MK; Park I; Ahn JH; Lee DH; Ryoo HM; Song C; Hong B; Hong JH; Ahn H
Ann Oncol; 2015 Nov; 26(11):2300-5. PubMed ID: 26347107
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E
J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma.
Cheng W; Kletas V; Kollmannsberger C; de Lemos M
J Oncol Pharm Pract; 2020 Jan; 26(1):67-73. PubMed ID: 30909792
[TBL] [Abstract][Full Text] [Related]
9. Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule.
Ito T; Yamamoto K; Furukawa J; Harada K; Fujisawa M; Omura T; Yano I
J Clin Pharm Ther; 2022 Jan; 47(1):81-88. PubMed ID: 34669974
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Sunitinib Alternative Prescription Schedules in Metastatic Kidney Cancer: A Study of 10 Cases.
Diallo H; Mhamdi HA; Elouarzazi S; Fadli M; Belbaraka R
Gulf J Oncolog; 2018 Jan; 1(26):33-36. PubMed ID: 29607820
[TBL] [Abstract][Full Text] [Related]
11. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
12. The Alternative 2/1 Schedule of Sunitinib is Superior to the Traditional 4/2 Schedule in Patients With Metastatic Renal Cell Carcinoma: A Meta-analysis.
Sun Y; Li J; Yang X; Zhang G; Fan X
Clin Genitourin Cancer; 2019 Oct; 17(5):e847-e859. PubMed ID: 31279483
[TBL] [Abstract][Full Text] [Related]
13. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong AJ; Halabi S; Eisen T; Broderick S; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; Lusk CM; Oberg S; George DJ
Lancet Oncol; 2016 Mar; 17(3):378-388. PubMed ID: 26794930
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Ohzeki T; Fukasawa S; Komaru A; Namekawa T; Sato Y; Takagi K; Kobayashi M; Uemura H; Ichikawa T; Ueda T
Int J Urol; 2014 Oct; 21(10):1065-8. PubMed ID: 24930736
[TBL] [Abstract][Full Text] [Related]
15. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S; Iacovelli R; Boni L; Rizzo M; Derosa L; Rossi M; Galli L; Procopio G; Sisani M; Longo F; Santoni M; Morelli F; Di Lorenzo G; Altavilla A; Porta C; Camerini A; Escudier B;
Ann Oncol; 2015 Oct; 26(10):2107-13. PubMed ID: 26216384
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
19. Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma.
Kawashima A; Uemura M; Kato T; Ujike T; Nagahara A; Fujita K; Imamura R; Yamanaka Y; Tomiyama E; Tanigawa G; Miyagawa Y; Yoshioka T; Miyake O; Nonomura N
Int J Clin Oncol; 2019 Jan; 24(1):78-86. PubMed ID: 30094693
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
